Prostate Cancer Patients With Cardiovascular Disease Had Higher Mortality After Starting Abiraterone Acetate

Patients with advanced prostate cancer who had pre-existing cardiovascular disease had higher risk of mortality in the six months after starting abiraterone acetate (Zytiga) treatment compared with those who had no pre-existing cardiovascular disease, according to data presented during a media preview of theĀ American Association for Cancer Research (AACR) Annual Meeting 2019, which will be …